The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Status
- RECRUITING
- Phase
- PHASE3
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- N/A
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE2
NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
- Status
- RECRUITING
- Phase
- PHASE2
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)
- Status
- RECRUITING
- Phase
- PHASE2
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2